Study of BNT317 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called BNT317 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if BNT317 is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer (solid tumor) that has spread or cannot be removed with surgery, and you have tried standard treatments or they are not right for you.
- You have at least one tumor that can be measured on a scan, and it has not been treated recently with radiation or other local therapies.
- Your blood counts and organ function (like liver and kidneys) are good enough for treatment.
- You have not had a stem cell or organ transplant, and you are not currently taking high-dose steroids or have uncontrolled high blood pressure or diabetes.
- Any brain metastases must be small, treated, stable, and not require steroids or seizure medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.